IACTA Pharmaceuticals Licenses NM133 from Nanomerics for Treatment of Dry Eye
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--IACTA Pharmaceuticals has acquired the North American rights to develop and commercialize NM133, an investigational medicine designed to help treat dry eye from its developer, Nanomerics, Ltd.